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critical role in assembly and stabilization of the
HIV-1 capsid
Ernest L Yufenyuy and Christopher Aiken*Abstract
Background: Lentiviruses exhibit a cone-shaped capsid composed of subunits of the viral CA protein. The intrinsic
stability of the capsid is critical for HIV-1 infection, since both stabilizing and destabilizing mutations compromise
viral infectivity. Structural studies have identified three intersubunit interfaces in the HIV-1 capsid, two of which
have been previously studied by mutational analysis. In this present study we analyzed the role of a third interface,
that which is formed between the amino terminal domain (NTD) and carboxyl terminal domain (CTD) of adjacent
subunits.
Results: We provided evidence for the presence of the NTD-CTD interface in HIV-1 particles by engineering
intersubunit NTD-CTD disulfide crosslinks, resulting in accumulation of disulfide-linked oligomers up to hexamers.
We also generated and characterized a panel of HIV-1 mutants containing substitutions at this interface. Some
mutants showed processing defects and altered morphology from that of wild type, indicating that the interface is
important for capsid assembly. Analysis of these mutants by transmission electron microscopy corroborated the
importance of this interface in assembly. Other mutants exhibited quantitative changes in capsid stability, many
with unstable capsids, and one mutant with a hyperstable capsid. Analysis of the mutants for their capacity to
saturate TRIMCyp-mediated restriction in trans confirmed that the unstable mutants undergo premature uncoating
in target cells. All but one of the mutants were markedly attenuated in replication owing to impaired reverse
transcription in target cells.
Conclusions: Our results demonstrate that the NTD-CTD intersubunit interface is present in the mature HIV-1
capsid and is critical for proper capsid assembly and stability.
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The mature HIV-1 capsid is a cone-shaped structure
formed by assembly of approximately 1500 subunits of the
viral CA protein into a lattice of hexamers, with
pentamers closing the ends [1,2]. The capsid lattice is sta-
bilized by intersubunit interactions within and between
hexamers. The amino-terminal and carboxyl-terminal do-
mains (designated NTD and CTD, respectively) of CA are
predominantly alpha-helical and fold independently [3,4].
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distribution, and reproduction in any mediumof the capsid and have defined protein interfaces in the
NTD and CTD through which the subunits interact [5-8].
These interfaces include a six-fold intra-hexameric NTD-
NTD interface [6,8]; a dimeric inter-hexamer interface
formed between CTDs [3,5,6,9]; and a CTD-CTD trimeric
interface that connects the hexamers [5]. The structures
have also revealed the presence of an NTD-CTD
intersubunit interface between adjacent CA subunits
within the hexamers [8].
The viral capsid plays a critical role in early events in
the HIV-1 life cycle. Following fusion of the HIV-1 par-
ticle with a susceptible host cell, the capsid undergoes
disassembly from the ribonucleoprotein complex in a
process termed uncoating. Uncoating is a poorly under-
stood stage in the HIV-1 life cycle. Mutagenesis studiesCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tice confer specific intrinsic stability to the HIV-1 capsid.
Mutations at the NTD-NTD and CTD-CTD intersubunit
interfaces affect capsid stability [5,10-12]. CA mutants
with reduced capsid stability often exhibit impaired infect-
ivity, suggesting that the intact capsid performs a critical
function following penetration into the target cell. Im-
aging studies of HIV-1 CA mutants in target cells further
provided evidence for a role of reverse transcription in
facilitating uncoating, suggesting that deviations in capsid
stability might affect reverse transcription [13,14]. Fur-
thermore, capsid-targeting cellular restriction factors that
block infection at an early phase of replication appear to
act by inducing premature uncoating in target cells
[15-17]. Mutagenesis studies have also shown that CA
surfaces are important for both particle assembly and
capsid formation, and CA mutants that exhibit abnormal
core morphology are poorly infectious [18-22]. Thus, the
emerging view is that the capsid is a critical component of
the virion whose structure, assembly, and disassembly re-
quire a better understanding for antiviral targeting. Be-
sides CA, other Gag components, including NC, are also
important for shaping the structure of the virion [23].
NTD-CTD intersubunit interactions were initially sug-
gested by in vitro kinetic assembly studies of full-length
CA protein and truncated N-terminus and C-terminus
proteins [24]. This initial suggestion was further en-
hanced by observations that hydrogen-deuterium (H/D)
exchange on in vitro assembled CA occurred slowly at
the NTD and at the CTD regions suggesting that these
regions are protected. Chemical crosslinking and high-
resolution mass spectrometry in the same study showed
that Lys 70 on one subunit is in proximity to Lys 182 on
a different CA subunit [25]. This interface was later vi-
sualized in atomic resolution in the crystal structure of a
CA hexamer [8]. Structural and genetic studies of other
retroviruses, specifically RSV and SIV (both showing
second-site suppressors), also indicated the presence of an
interdomain interaction in the capsid involving the NTD
of one subunit and the CTD of an adjacent subunit
[26-28]. This is consistent with the overall structural con-
servation exhibited by retroviral CA proteins [29-33].
In HIV-1, the NTD-CTD interface is formed by helices
4 and 7 on the NTD of one subunit and helices 8 and 11
on the CTD of the adjacent subunit [6,8]. The NTD-CTD
interface is present in assemblies of recombinant CA and
in disulfide-stablized CA hexamers and pentamers; fur-
thermore, studies of HIV-1 virus-like particles by H/D ex-
change demonstrated that peptides mapping to this region
of the CA-NTD were protected from solvent, suggesting
that the interface is present within the viral capsid [34].
Nonetheless, neither the structure of the interface in the
context of mature HIV-1 particles, nor its role in HIV-1
replication, has been studied in detail.To investigate the role of the NTD-CTD intersubunit
interface in capsid assembly and stability, we used the
crystal structure of the HIV-1 CA hexamer as a guide to
design a panel of HIV-1 mutants encoding substitutions
in the NTD-CTD interface. We confirm via engineered
disulfide crosslinking that the NTD-CTD interface is
present within HIV-1 particles. Analysis of a panel of
single amino acid substitution mutants for capsid func-
tions in vitro and ex vivo revealed that the interface is
critical for HIV-1 capsid structure and stability, and for
viral infectivity.
Results
Engineered cysteine substitutions at the NTD-CTD
interface result in spontaneous disulfide crosslinking of
CA in virions
The X-ray structure of the HIV-1 CA hexamer capsid
revealed the presence of an intermolecular interface be-
tween the NTD of one CA subunit and the CTD of the
adjacent subunit [8]. To test whether the NTD-CTD
interface is detectable within the viral capsid lattice, we
generated full-length HIV-1 molecular clones encoding
double Cys substitutions across the interface. Using the
structural display program Pymol, we quantified distances
between interface residues in the X-ray structure of the
HIV-1 CA hexamer (PDB code 3H4E, Figure 1A). Dis-
tances within ~5 Å (Cβ-Cβ) were targeted. We reasoned
that if the interface is present within the viral mature
capsid, adjacent subunits with mutant cysteine residues
should form spontaneous disulfide crosslinks. In a previ-
ous study, we had successfully employed this approach to
provide evidence for the existence of a CTD-CTD trimeric
interface in mature HIV-1 particles [5]. We engineered a
total of 5 Cys pairs spanning the interface (Figure 1). The
mutant viruses were produced by transfection of 293T
cells with the mutant plasmids, pelleted, and analyzed for
spontaneous CA-CA crosslinking by non-reducing SDS-
PAGE and immunoblotting. When tested on TZM-bl
cells, the double Cys mutants were not infectious (data
not shown). The A64C/L211C and M68C/L211C mutants
did not form crosslinked CA bands higher than dimers
(Figure 1B), but the M144C/M215C mutant exhibited
dimer and trimer CA species, possibly as a result of
geometric constraints. Q63C/Y169C and M68C/E212C
particles exhibited ladders of oligomers corresponding
to dimers, trimers, tetramers, pentamers, and hexamers
(Figure 1A). Of the mutants, M68C/E212C exhibited the
greatest extent of crosslinking. Upon treatment with redu-
cing agent, all higher CA bands of the double mutants
were converted into the monomeric form (Figure 1C),
demonstrating that the oligomeric species were stabilized
by disulfide bond formation. When M68C/E212C virions
were analyzed by transmission electron microscopy











































































































Q63 Y169  3.6 
A64 L211 7.5 
M68 L211 5.2 
M68 E212 5.4 
M144 M215 6.5 
C198 C218 4.2 
Figure 1 CA subunits virions with engineered cysteines at the NTD-CTD capsid interface spontaneously crosslink into hexamers in HIV-1
particles. (A) A view of the NTD-CTD interface showing the NTD helices 4 and 7 (blue) from one subunit in close proximity to the CTD helices 8 and
11 (red) from another subunit (PDB: 3H4E). Residues mutated to cysteines for crosslinking are shown in orange and are connected by green dotted
lines. The two endogenous Cys are shown for comparison. Distances in angstroms (Å) from a Cβ-carbon of one amino acid residue on NTD1 of one
subunit to a Cβ-carbon on a second amino acid residue on CTD2 from a different subunit are shown. The Cβ-Cβ distance between endogenous
cysteines is shown for comparison. (B, C, and D) Immunoblot analysis of viral lysates. Pelleted particles were dissolved in 1X SDS sample buffer in the
absence (B) or presence (C) of β-mercaptoethanol. Samples were then separated by SDS-PAGE and analyzed by immunoblotting with CA-specific
antibody. (D) Analysis of the single mutants M68C and E212C under non-reducing conditions.
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the initial assembly of the immature particle. The capsids
varied in size and shape, but still exhibited spherical and
conical structures (data not shown). Regarding the M68C/
E212C mutant, analysis of virus mutants containing either
individual cysteine substitution revealed that crosslinking
was dependent on the presence of both substitutions
(Figure 1D). Collectively, these data confirm that the NTD-
CTD intersubunit interface is present within the hexameric
unit in the capsid lattice. The formation of hexameric
crosslinking within the mutant virions suggested that theNTD-CTD interface is likely to play an important role in
capsid structure and function.
NTD-CTD interface substitutions impair HIV-1 replication
in T cells
To study the role of the NTD-CTD interface in HIV-1
capsid structure and function, we targeted amino acids at
positions in the interface for mutagenesis. To this end,
HIV-1 proviruses containing single substitutions in the
NTD and CTD were produced. The mutants included
fourteen alanine substitutions and one aspartic acid
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face in the crystal structure, showing each position that
was targeted. To characterize and evaluate the effects of
the mutations on HIV-1 replication, we quantified virus
accumulation in cultures of the human CEM T cell line.
Cultures were inoculated with wild type and mutant vi-
ruses at low MOI, and the cultures were monitored for
the accumulation of p24 or RT activity (for mutants not
recognized by our ELISA primary antibody) in the culture
supernatants. As expected, the wild type virus replicated
efficiently in CEM cultures, reaching peak levels at day
6–9 days post-inoculation. By contrast, the Q63A,
E75A and R167A mutants were markedly delayed in
replication, peaking at days 18 or 15, and exhibiting
maximum p24 levels lower than that of the wild type
(Figure 2B and 2C). The delayed replication of the mu-
tants may have been due to reversion or accumulation
of additional mutations, though this was not specific-
ally examined. The duplicate cultures exhibited similar
results, arguing against pseudoreversion, which would
likely be stochastic. Q176A was delayed by 3 days, but
reached a similar peak level as the wild type (Figure 2C).
The Q179A mutant replicated with nearly wild-type kinet-
ics (Figure 2C). However, the remaining ten mutants failed
to replicate, including five NTD substitutions (H62A,
A64D, M68A, E71A, K140) and five CTD mutants (R162A,














WT - 100 +++ 50
H62A Helix 4 1.0 ± 0.3 - 10
Q63A Helix 4 27 ± 3 + 15
A64D Helix 4 0 ± 0.1 - 35
M68A Helix 4 1.0 ± 1 - 10
E71A Helix 4 18 ± 4 - 20
E75A Helix 4 13 ± 3 + 20
K140A Helix 7 1.0 ± 0 - 20
R162A Helix 8 0 ± 0.2 - 35
V165A Helix 8 1.0 ± 1 - 25
D166A Helix 8 1.0 ± 1 - 35
R167A Helix 8 11 ± 2 + 35
Q176A Helix 8 25 ± 3 ++ 30
Q179A Helix 8 62 ± 12 +++ 35
E180A Helix 8 4 ± 1 - 20
M215A Helix 11 0 ± 0.3 - 20
@ +++, replicates like wild type; ++, 3 days delayed; +, 15–18 days delayed; -, no re
# mature cores exhibit an electron-dense core region, which is either bar-shaped, co
ND; not determined.
a: conical but morphologically aberrant cores.most changes at the NTD-CTD interface resulted in severe
impairments in replication in primary T cells.
Most changes in the NTD-CTD interface do not affect HIV-
1 particle production
Substitutions in CA can inhibit particle production by
perturbing lattice interfaces, altering Gag cleavage, or
inhibiting protein folding or stability [35-38]. To assess
the effects of NTD-CTD interface substitutions on par-
ticle production, we transfected 293T cells and deter-
mined the quantity of viral proteins released into culture
supernatants by RT activity assays. In most cases, par-
ticle production was similar to that of the wild type, ex-
cept for H62A and K140A, which exhibited reduced
particle production (Figure 3A). The reduced particle
yield of the latter two mutants was not due to poor ex-
pression of Gag in the producer cell, as determined by
immunoblotting analysis of lysates of the transfected
cells (data not shown). To determine whether Gag pro-
cessing was altered by the mutations, we pelleted the
viral particles and analyzed the viral proteins by SDS-
PAGE and immunoblotting with a CA-specific antibody.
Most of the mutants exhibited a normal banding pat-
tern, suggesting that the observed replication defects
were not caused by aberrant processing of Gag precur-
sors. Exceptions were the H62A, K140A and M215A















+ 14 ± 2 Normal Yes 100
- 1.1 ± 0.4 ND No 1.3 ± 0.5
+ 5.2 ± 0.2 Accelerated Yes 50 ± 14
- 1 ± 0.6 ND No 1.3 ± 0.5
- 0.8 ± 0.3 ND No 1.3 ± 0.5
+ 6.3 ± 2 Normal Yes 49 ± 6.2
+ 3.6 ± 1 Accelerated Yes 34 ± 6.2
- 0 ± 0 ND No 1.0 ± 0.8
+ 0.2 ± 0.1 ND No 1.7 ± 0.5
a 31 ± 4 Slowed Yes 2.0 ± 0.8
- 1 ± 0.1 ND No 1.3 ± 0.5
+ 6.4 ± 1.1 Accelerated No 32 ± 5.2
+ 8.1 ± 2 Normal Yes 83 ± 13
+ 13 ± 2 Normal Yes 94 ± 7.9
- 5.1 ± 1.4 Normal Yes 30 ± 1.7
- 0.5 ± 0.1 ND No 1.5 ± 0.5



































































Figure 2 Impaired replication of NTD-CTD mutants in CEM cells. (A) Structural view of the NTD-CTD interface showing two different
subunits, NTD1 (blue) and CTD2 (red) and the side chains of residues target for mutagenesis. (B and C) CEM cells were inoculated with 5 ng of
virus or an equivalent quantity based on RT units. Supernatants were sampled from the culture media after every 3 days as indicated and viral
accumulation analyzed by p24 ELISA or by in vitro RT assay. The results shown are the mean values of duplicate determinations.
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was not determined. Conceivably, these three mutations
might have altered the tertiary and quaternary structure of
the CA protein, such that sites not normally cleaved by
proteases became exposed to enzyme activity resulting in
non-canonical cleavage. Because proteolytic processing of
Gag is initiated during HIV-1 particle assembly, the aber-
rant cleavage could also contribute to the impaired
particle production observed for the H62A and K140A
mutants (Figure 3A).
To determine the consequences of NTD-CTD inter-
face mutations on HIV-1 infectivity, we titrated the par-
ticles on TZM-bl indicator cells. Cells were lysed and
quantified for luciferase activity, which was normalized
by the input levels of RT activity in the inocula. A major-
ity of mutants including Q63A, E71A, E75A, R167A,
Q176A, E180A exhibited moderate-to-severe reductions
(~10-30% of WT) in infectivity (Figure 3C). Infectivity
was virtually abolished (<2% of WT) by the mutations
H62A, A64D, M68A, K140A, V165A, D166A, M215A,
while the infectivity of the Q179A mutant was similar to
that of the wild type. These results suggest that the im-
paired replication by the mutant viruses is due to an
early defect in the viral life cycle, since viral productionafter transfection was unaffected, except for the two
aforementioned mutants (H62A and K140A).
Point mutations at the NTD-CTD interface alter the level
of CA associated with purified HIV-1 cores
The HIV-1 capsid is a metastable structure, and mutations
in CA that alter the intrinsic stability of the capsid are
generally deleterious to infectivity [5,10,11]. The X-ray
crystal structure of the CA hexamer suggested that NTD-
CTD intersubunit interactions likely contribute to capsid
lattice stability [8]. To test this hypothesis, we purified
viral cores from the mutant particles and quantified the
percentage of CA cosedimenting with the cores. For the
wild type, a mean value of 14.3% was obtained from three
independent experiments. This value is consistent with
previous reports that only a minor fraction of CA in vi-
rions participates in capsid assembly [5,11,14,39-41]. By
contrast, a majority of the NTD-CTD interface mutants
exhibited levels of core-associated CA lower than that of
the wild type (Figure 3D). Based on the results, we catego-
rized the mutants as follows: hyperstable (V165A); mo-
derately reduced stability (Q63A, E71A, E75A, R167A,
Q176A, E180) and highly unstable (H62A, A64D, M68A,












































































































































































































































Figure 3 Mutations at the NTD-CTD intersubunit interface impair HIV-1 infectivity and alter capsid stability. (A) Production of viral
particles as measured by RT activity. (B) Immunoblot analysis of viral lysates. Virions were collected from transfected 293T cells, pelleted, and
analyzed by SDS-PAGE and immunoblotting with a CA specific polyclonal antibody. (C) Single-cycle infectivity of the mutant virions. Virion stocks
were titrated on TZM-bl reporter cells and the extent of infection was determined by quantification of luciferase reporter activity in cell lysates.
Values were normalized by the corresponding values of reverse transcriptase activity in the inocula. Results shown are the mean values of three
independent experiments, with error bars representing one SD. (D) Quantification of core-associated CA. Cores were purified from the
concentrated virions, and the levels of the core-associated CA were determined as a percentage of the total virion-associated CA. The values
shown are the means of three independent experiments; error bars represent one SD.
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the impaired infectivity for the mutant viruses (Figure 3C).
Cores from a subset of NTD-CTD interface mutants
exhibit altered rates of uncoating in vitro
To further analyze the effects of the mutations on HIV-1
capsid stability, we quantified the uncoating of cores puri-
fied from the Q63A, E71A, E75A, V165A, R167A, Q176A,
Q179A, and E180A mutants. Samples of purified cores
were diluted into buffer and incubated at 37°C for various
time periods, after which the cores were pelleted and the
extent of uncoating determined by quantifying the CA
present in the supernatant and pellet. We observed altered
rates of uncoating for a subset of the mutants. Cores from
the Q63A, E75A, and R167A mutants uncoated more rap-
idly than the wild type, while E71A, Q176A and Q179A
cores uncoated with kinetics similar to the wild type
(Figure 4A-C). E180A cores reproducibly uncoated slightly
faster than wild type cores in three independent experi-
ments. By contrast, V165A cores uncoated more slowly
than the wild type (Figure 4A), in concordance with theelevated level of core-associated CA exhibited by this mu-
tant (Figure 3D). Based on the collective results shown in
Figure 3D and Figure 4, we conclude that a majority of
mutations in the NTD-CTD interface destabilize the viral
capsid, while the V165A renders the capsid hyperstable
(summarized in Table 1).
NTD-CTD interface mutants exhibiting highly unstable
capsids are impaired for abrogation of restriction by
TRIMCyp
TRIM5 host restriction factors inhibit retrovirus infec-
tion by inducing premature uncoating in target cells
[17,42-44]. Restriction by these factors is saturable and
can be overcome in trans by virus-like particles. We
have shown that saturation of restriction is dependent
on the stability of the HIV-1 capsid [39,45]. Thus, the
ability of HIV-1 particles to enhance infection of an
HIV-GFP reporter virus in trans can be a useful probe
of HIV-1 uncoating in target cells. To probe the stability
of the NTD-CTD interface mutants in vivo, we
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Figure 4 NTD-CTD CA mutant cores undergo accelerated
uncoating in vitro. Purified HIV-1 cores were diluted in STE buffer
and incubated at 37°C for the indicated times. After pelleting the
particles, the extent of uncoating was determined by quantifying CA
levels in the pellets and supernatants. Note that variations in
uncoating can occur from batch-to-batch isolated cores; hence for
each panel analyzed, cores were isolated at the same time. Shown
are the mean values of duplicate determinations, with error bars
representing the range of values. The results are representative of a
minimum of two independent experiments for each mutant.
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reporter virus in OMK cells, which endogenously
express TRIMCyp. CA mutants with moderately reduced
capsid stability (Q63A, E71A, E75A, R167A, Q176A,
Q179A, E180A), as well as the hyperstable mutant
V165A, enhanced infection of HIV-GFP virus in trans
(Figure 5A and 5B). By contrast, mutants with highly un-
stable capsids (H62A, A64D, M68A, K140A, R162A,
D166A and M215A) were markedly impaired in their
ability to overcome restriction by TRIMCyp (Figure 5C).
These results suggested that the NTD-CTD mutants
with unstable capsids undergo premature uncoating in
target cells.Mutations in CA can compromise the ability of the virus
to engage TRIMCyp either directly by altering recognition,
or indirectly by inducing premature uncoating. We
previously demonstrated that the addition of mutations
preventing cleavage between CA and NC can rescue
the ability of mutants with unstable capsids to overcome
restriction, most likely by stabilizing the capsid [39,45].
Although it seems unlikely that NTD-CTD interface sub-
stitutions would directly alter recognition by TRIMCyp,
which binds to an exposed CA loop on the outer surface of
the capsid, we nonetheless analyzed mutants containing
both the NTD-CTD substitutions together with the CA-
NC cleavage site mutants. In this context, all of the un-
stable mutants except M68A enhanced infection by HIV-1
GFP (Figure 5D). Thus for the majority of the unstable
mutants, the failure to abrogate restriction in OMK cells
can be attributed to the instability of their capsids and not
to a direct effect on the CA substitutions on recognition by
TRIMCyp. These data support the conclusion that NTD-
CTD interface residues contribute to proper uncoating in
target cells.Mutations in the NTD-CTD interface impair HIV-1 reverse
transcription in target cells
The majority of the NTD-CTD interface mutants released
normal quantities of particles that were poorly infectious,
indicative of an early post-entry defect. Previous studies
from our laboratory and others have shown that capsid-
destabilizing mutations are often associated with impair-
ments in reverse transcription [10,18,46]. Therefore, we
employed stage-specific PCR to quantify the ability of the
NTD-CTD capsid mutants to undergo reverse transcrip-
tion in target cells. The mutants exhibiting altered capsid
stability displayed markedly reduced accumulation of late
reverse transcripts in vivo (Figure 6). Additional experi-
ments revealed that the mutants also produced reduced
levels of early products (full-length minus strand; data not
shown). Our results show that the reduced infectivity of the
NTD-CTD interface mutants is associated with impaired
reverse transcription. Reverse transcription appeared to be
correlated with the degree of capsid stability, as partially
unstable CA mutants accumulated less DNA compared to
WT, and no DNA products were detected for highly un-
stable mutants (Figure 6). The hyperstable mutant V165A
was also impaired for reverse transcription in target cells.
To determine whether the decrease in reverse tran-
scription of the CA mutants in target cells is due to a
decrease in virion-associated RT activity, we assayed
virus stocks for exogenous RT activity and for CA anti-
gen in parallel. The results of the two assays were con-
cordant, indicating that the CA substitutions did not
affect the levels of active RT enzyme within the particles
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Figure 5 NTD-CTD CA mutant capsids fail to abrogate rest riction by TRIMCyp. OMK cells were co-inoculated with fixed amount (5 ng) of
HIV-GFP and the indicated quantities of CA mutant viruses. (A) and (B) are separated for clarity, while (C) and (D) show abrogation activity for the
mutants in the wild type and the CA-NC cleavage mutant background, respectively. The values shown are the average of duplicate
determinations and are representative of two independent experiments.
Yufenyuy and Aiken Retrovirology 2013, 10:29 Page 8 of 14
http://www.retrovirology.com/content/10/1/29Ultrastructural analysis of NTD-CTD mutant virions
To examine potential effects of the NTD-CTD interface
substitutions on core structure, we performed ultra-thin
section transmission electron microscopic (TEM) analysis
of WTand mutant virions produced from transfected HeLa





























































Figure 6 NTD-CTD CA mutants with altered capsid stability are
impaired in reverse transcription in target cells. HeLa-P4 cells
were inoculated with equal quantities of WT or mutant viruses.
Cultures were harvested 8 hr. after infection and DNA isolated and
assayed for second-strand transfer products by qPCR. Shown are the
mean values and error bars represent the standard deviations from
three independent experiments.wild type HIV-1 proviral construct exhibited various stages
of morphogenesis, including budding particles and imma-
ture and mature particles, with mature particles exhibiting
conical, tubular, and spherical capsids near the cell surface,
depending on the plane of sectioning (Figure 7). The con-
ical and spherical capsids also contained an electron-dense
nucleoid typical of the HIV-1 ribonucleoprotein complex.
Immature particles were apparent in both the wild type and
CA mutants, but occurred at a slightly higher frequency for
the mutants (Table 1). Analysis of size of the particles dem-
onstrated that most of the mutations did not alter the
diameter of the particles, with three exceptions (Figure 8).
Statistical analysis of the results indicated that E75A,
K140A, and V165A each exhibited slightly elevated virion
diameters compared to wild type. The E75A mutation was
previously associated with altered particle size, as the
double mutant E75A/E76A exhibited enlarged particles
[20]. A study of HIV-1-RSV chimeric viruses also observed
a link between CA and the size of immature particles [33].
With respect to capsid morphology, cones and tubes
were also apparent in six of the mutants (Q63A, E75A,
R162A, R167A, Q176A, Q179A) (Figure 7). However, seven
of the mutants (H62A, A64D, M68A, K140A, D166A,
E180A and M215A) lacked the conical morphology of the
wild type (Figure 7) but retained the electron-dense internal
structure of the RNP complex. E71A particles exhibited
multiple core-like internal structures without clear conical















Figure 7 Electron microscopy of NTD-CTD interface mutants. HeLa cells were transfected with R9 plasmids containing either WT or alanine
mutations. 24 hr post transfection, the cells were fixed in buffer containing 2.5% glutaraldehyde. Following embedding and staining, ultrathin
sections were then examined in a FEI Tecnai Spirit Twin transmission electron microscope. Scale bars represent 100 nm. Arrows indicate particles
with conical capsids.
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ing greatly in size and shape. Overall, the effects of the mu-
tations on capsid morphology suggest that residues at the
NTD-CTD interface are important for proper capsid struc-
ture as well as stability.
Discussion
Our previous studies identified side chains in the NTD
and CTD that are critical for HIV-1 capsid stability
[11,47]. At the time of those studies, the positions of the
mutations in the CA hexamer were not known, as the
high-resolution structure of the hexamer had not yetbeen reported. Subsequent studies showed that several
of the NTD substitutions that perturbed capsid stability
(P38A, E45A, T54A) were located at the NTD-NTD
interface [8], while some of the CTD substitutions
(K203A, Q219A) were present at the 3-fold CTD-CTD
interhexameric interface [5]. In the present study, we fo-
cused on the role of the NTD-CTD intersubunit inter-
face, which was not well characterized at the time of the
previous studies, in HIV-1 capsid structure and function.
High-resolution structural studies provided the foun-
dation for this investigation. The CA hexamer structure
suggested that the NTD-CTD interface is likely to



























































Figure 8 Effects of NTD-CTD interface substitutions on HIV-1
particle size. The diameter of HIV-1 particles was quantified. Shown
are the mean values, with error bars represent one
standard deviation.
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and other retroviral capsids demonstrated that this inter-
face is present in the capsid lattice formed by assembly
of CA in vitro [6,8,24-28,34]. However, the role of the
NTD-CTD interface in the virion and its contribution to
capsid function had not been demonstrated.
Our engineered disulfide crosslinking data confirms that
the NTD-CTD interface is a component of the native HIV-
1 capsid lattice. Crosslinking between Cys residues at posi-
tions 68 and 212 resulted in the formation of monomer,
dimer, trimer, tetramer, pentamer and hexamer bands. Lack
of crosslinked CA species in the single mutants (M68C and
E212C) showed that the banding results from disulfide
bonding between the engineered cysteines (Figure 1D).
Further evidence for the NTD-CTD hexameric inter-
face was also provided by crosslinking observed in the
Q63C/Y169C, A64C/L211C, M144C/M215C and M68C/
L211C mutants, though at reduced efficiency (Figure 1B),
which was not enhanced upon chemical oxidation with
copper O-phenanthroline (our unpublished observations).
Engineered crosslinking provides an experimental probe
for the formation of an NTD-CTD interface in mutant vi-
rions. We have recently employed this approach to study
the formation of the individual capsid intersubunit inter-
faces during maturation [48], and it may also prove useful
for studying the effects of small molecules on capsid as-
sembly and structure.
We also observed that amino acid substitutions at the
NTD-CTD interface affect capsid assembly. Three of the
mutants (A64D, M68A, D166A) exhibited normal Gag
processing, and produced particles at wild type levels.
However, the virions had significant reductions in thenumber of conical capsids (Figure 7, Table 1). D166 is an
interdomain helix-capping amino acid, whose interac-
tions with helix 4 of an adjacent subunit provides an
amino terminal capping for the NTD-CTD interaction
[8]. Other substitutions at the interface, including H62A,
K140A and M215A, also perturbed capsid structure.
However, these three substitutions led to altered pro-
cessing of Gag, suggesting that the changes may affect
capsid structure through maturation defects. A previous
study of H62A had also reported that this mutant is im-
paired for HIV-1 capsid assembly [19]. H62 occupies the
hydrophobic core of the NTD-CTD interface forming
stacking interactions with F32 and Y145 [6,8]. The
phenotype of the H62A mutant is also reminiscent of
the effects of CAP-1, a small molecule capsid assembly
inhibitor that binds the NTD pocket and disrupts the
packing of the Phe32 and Tyr145 aromatic side chains
[8,49]. K140 and M215 lie in close proximity to the
helix-capping amino acids R143 and Q219, respectively
[8]. Their proximity to helix-capping amino acids sug-
gest that substitutions at these positions may alter con-
tacts at the NTD-CTD interface and perturb capsid
assembly. Previous work from another group had shown
that the NTD-CTD interface substitutions Y169A and
L211A also induced severe Gag processing defects [35],
which may result from the generation of novel cleavage
sites or from structural alterations induced by the
mutations.
A major finding from this work is that substitutions at
the NTD-CTD interface alter capsid stability (Table 1).
Most of the substitutions at the NTD-CTD interface
produced virions with unstable capsids, all of which
were poorly infectious. The mutations that destabilized
the capsid in vitro also resulted in accelerated uncoating
in target cells, as indicated by the reduced ability of the
mutant particles to abrogate restriction by TRIMCyp.
The in vitro uncoating data agreed well with the abroga-
tion of restriction results. However, Q63A, R167A, and
E180A were exhibited rapid uncoating in vitro, but
these mutants abrogated restriction with wild type effi-
ciency. Our understanding of the mechanism of restric-
tion abrogation is limited; however, we have shown that
addition of a second-site suppressor mutation restores
the abrogation activity of the P38A mutant without re-
versing its intrinsic capsid instability [14], suggesting
that mutations can perturb uncoating in target cells
without altering the biochemical stability of the capsid.
The Q179A substitution also had no apparent effect on
capsid stability or viral infectivity. Structurally, Q179 is
located at the end of helix 8 and is near N57, Q63 and
M66 in the NTD. Currently, it is not clear why the
Q179A substitution was not deleterious to capsid func-
tion; we surmise that the location of this side chain near
the edge of the interface may be a factor.
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unstable (Figure 3D and Figure 5C). The mutant was im-
paired for reverse transcription in target cells (Figure 6),
was poorly infectious and was impaired for abrogation.
We attribute the phenotype of this mutant to a capsid
stability defect. Structurally, R162 is near the stack
formed by Y145, H62 and F32; the R162 guanidinium
group is thought to stabilize the stacking of these aro-
matic side chains [8]. It is plausible that the substitution
of alanine at this position changes the juxtaposition of
the Y145 and F32 side chains at the NTD-CTD inter-
face, thus altering the structure at the interface and ren-
dering the capsid unstable.
In an earlier study we reported that E45A exhibited an
impairment in reverse transcription in target cells [10].
More recently, we observed that this mutant is, in fact,
competent for reverse transcription in target cells [14]. In
the present work, we observed that the hyperstable V165A
mutant is impaired for reverse transcription, like the un-
stable mutants (Figure 6). Preliminary analysis of the
cores purified from V165A by immunoblotting revealed
that the mutant cores are enriched in unprocessed Gag
and Gag-Pol (our unpublished observations). We specu-
late that the presence of these intermediates prevented re-
verse transcription by interfering with the activity of the
processed RT or by perturbing capsid structure.
Our results highlight the NTD-CTD intersubunit inter-
face as a potentially attractive target for therapeutic inter-
vention. Recently, small molecule inhibitors targeting
HIV-1 CA have been identified [50-53]. One of these, PF-
3450074 (PF74), binds to a pocket in the NTD located
near the NTD-CTD interface and destabilizes the capsid
[41,52]. Substitutions in the interface can lead to resist-
ance by blocking the binding of PF74 [41], but these mu-
tations may also result in reductions in viral fitness.
Another small molecule, CAP-1, has been shown to alter
subunit interactions at the NTD-CTD interface [8,49,53].
Our finding that many NTD-CTD interface mutants
exhibit impaired replication suggests that inhibitors
targeting this interface may exhibit a high barrier to
emergence of resistance. Further efforts to design
capsid-targeting HIV-1 inhibitors will benefit from a
thorough understanding of the structure and function
of the viral capsid.
Conclusions
Our results show that the NTD-CTD intersubunit inter-
face is critical for both HIV-1 capsid structure and stabil-
ity. Engineered disulfide crosslinking studies confirmed
that the interface is present in the mature viral capsid.
The multiple effects of mutations at the interface suggest
that small molecules targeting this region of the capsid
could be effective antivirals.Methods
Cells and viruses
The 293T, HeLa-P4, HeLa, TZM-bl, and OMK cells used
in this study were cultured in Dulbecco’s modification of
Eagle’s medium (DMEM; Cellgro) supplemented with
10% fetal bovine serum (FBS), penicillin (50 IU/ml), and
streptomycin (50 μg/ml). All cells were cultured in a hu-
midified 37°C incubator containing 5% CO2. CEM cells
were cultured in RPMI 1640 medium supplemented with
10% FBS, penicillin (50 IU/ml), streptomycin (50 μg/ml).
Point mutations in the CA region of the R9 HIV-1 proviral
plasmid were introduced by PCR mutagenesis. The mutant
viral fragments generated by PCR were reintroduced into
R9 with the unique restriction site pairs BssHII-ApaI,
Spe1-ApaI, and BssHII-Spe1, depending on the location of
the residue on the CA region. The regions of the mutants
insert on the viral plasmid corresponding to the PCR-
generated fragment were sequenced to confirm the presence
of these mutations and absence of extraneous mutations.
Viruses used for the abrogation-of-restriction assay were
Env-deficient R9 mutants pseudotyped by the vesicular sto-
matitis virus glycoprotein (VSV-G) [39].
Virus stocks were produced by calcium phosphate
transient transfection [54] of 293T cells in which 20 μg
of plasmid DNA was used per 2.0 × 106 cells in 10 cm
dishes as previously described [10], or proviruses were
produced by cotransfection of Env-defective proviral
constructs with plasmid pHCMV-G [55]. 12–16 hr after
transfection, the culture media was removed, and the
cells were washed with sterile PBS before adding fresh
media. The culture supernatants were harvested 48 hr
after transfection and filtered through a 0.45 μm pore-
size filters. Viral aliquots were frozen at −80°C and virus
production quantified by p24 ELISA as previously de-
scribed [56] or by RT activity assay [57].
Single-cycle assay of HIV-1 infectivity
Viral infectivity was assessed by titration on TZM-bl
cells [58]. The TZM-bl cell line is a HeLa cell clone
engineered to express CD4+, CXCR-4 and CCR5. These
cells contain Tat-responsive luciferase and LacZ re-
porters. HIV-1 viral stocks were serially diluted in cul-
ture medium containing polybrene or DEAE-dextran
(8 μg/ml and 20 μg/ml, respectively), and samples (100
μl total volume) were used to inoculate TZM-bl target
cells seeded the day before (15,000 cells per well in 96-
well plates). The cultures were maintained for an add-
itional 48 hr prior to lysis and detection with a lucifer-
ase substrate, (Steady-Glo, Promega). Luminescence in
relative light units (RLU) values were quantified in a
Topcount instrument (Perkin Elmer). Measurements
were normalized by RT or p24 to calculate the relative
infectivity of the viruses in RLU/RT or RLU/p24.
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Viruses were pelleted by ultracentrifugation (100,000 ×g,
30 min) through a 20% sucrose cushion. The pellets
were dissolved in SDS sample buffer in the presence or
absence of β-mercaptoethanol. Samples were heated at
95°C for 5 min and then analyzed by SDS-PAGE. CA
was detected by immunoblotting using a rabbit poly-
clonal anti-CA antibody.
Transmission electron microscopy
Cultured HeLa cells were transfected with 2.5 μg of viral
DNA plasmids using the TransIT-HeLaMonster trans-
fection kit (Mirus) according to the manufacturer’s
protocol. 24 hr after transfection, cells were washed with
phosphate buffered saline (PBS) and fixed with 2.5% glu-
taraldehyde. The fixed cells were detached from the
plates by gentle scraping, pelleted by centrifugation at
4°C and the pellet incubated for 3 hr in an ice-water
bath. Following incubation, the cells were washed several
times with PBS and the cell pellets were shipped to Elec-
tron Microscopy BioServices (Gaithersburg, MD) for
embedding, sectioning, and microscopic examination.
Pellets were post-fixed in 1% osmium tetroxide and
washed in ultra pure water. The samples were then bloc-
stained with 2% uranyl acetate and dehydrated in etha-
nol. Ultra-thin sections were cut and mounted onto 200
mesh copper grids and post-stained with uranyl acetate
and Reynolds’s lead citrate; and examined in a FEI
Tecnai Spirit Twin Transmission Electron Microscope
at 80kV at a minimum magnification of 30,000X. At
least 40 different grids from each sample were analyzed,
and over 200 particles from random fields of wild type
and mutant virions were examined, and a minimum of
10 high-resolution images were acquired for each sam-
ple. Between 15 and 40 particles were evaluated for par-
ticle diameter by measuring the diameter from prints of
the electron micrographs. Measurements were made
with a digital vernier caliper and scaled using the size
bars on the micrographs.
Isolation of HIV-1 cores
HIV-1 cores were isolated and characterized as previ-
ously described [40]. For each virus, the level of core-
associated CA was determined as a percentage of the
total CA in the gradient (based on ELISA). We used a
commercial ELISA (SAIC, Frederick) to analyze the
D166A and R167A mutants, which were not detected by
our standard ELISA.
In vitro uncoating assay
The assay was carried out as previously reported [40],
with the following modifications. Frozen aliquots of
purified HIV-1 cores (300 μl) were thawed and diluted
in 300 μl of cold STE buffer. 100 μl of the diluted coreswere mixed with 150 μl of 1X STE buffer and incubated
at 37°C in a final concentration of 10 μg/ml of BSA. Im-
mediately following incubation, the reaction was stopped
by incubation in an ice-water bath for 10 min and then
centrifuged at 100,000 ×g (Beckman TLA-55 rotor at
45,000 rpm) for 20 min at 4°C to pellet the remaining
cores. The supernatant was saved, while the pellet was
dissolved in 250 μl of p24 ELISA sample diluent (10%
calf serum and 0.5% Triton X-100 in phosphate-buffered
saline). The CA content in both fractions (pellet and
supernatant) was quantified by p24 ELISA, and the ex-
tent of uncoating was determined as the ratio of CA in
the supernatant to the total CA quantity in the reaction.
It should be noted that variations in wild type uncoating
can occur from batch-to-batch preparations of cores,
hence wild type and mutant cores shown for each
uncoating analysis were isolated at the same time.
Abrogation-of-restriction assay
The reporter virus, HIV-1-GFP pseudotyped with VSV-
G, was used to infect OMK (owl monkey kidney) cells as
previously reported [39]. 20,000 cells per well in 12-well
plates were seeded 24 hr prior to inoculation. To deter-
mine the appropriate dose of the reporter virus to use,
the virus was initially titrated on OMK cells. Based on
the titration results, we determined the dose of GFP re-
porter virus to use to achieve an infection level of ~0.5%.
The reporter virus together with increasing concentra-
tions of test viruses was inoculated onto OMK cells in 600
μl final volume containing 8 μg/ml polybrene. The inocu-
lum was removed and the medium replenished 24 hr later.
48 hr post-inoculation, cells were dissociated with trypsin
and fixed by addition of an equal volume of PBS
containing 4% paraformaldehyde. GFP expression was
quantified by flow cytometry using an Accuri C6 flow
cytometer. The percentage of GFP-expressing cells was
determined from a minimum of 10,000 cells analyzed.
Assay of reverse transcription in target cells
For analysis of viral DNA synthesis by qPCR, viruses
were produced in 293T cells using the 293T transfection
reagent (Mirus), according to the manufacturer’s proto-
col. We found this transfection procedure to be effective
at for minimizing levels of carryover plasmid DNA,
thereby providing acceptable backgrounds in the PCR-
based assay of reverse transcription. Briefly, 8 hr post
transfection the media was removed and the cells
washed with PBS before replenishing media. Viruses
were harvested 36–48 hr later. Virus stocks were
pretreated with 20 μg of DNase 1, 10 μM MgCl2, and 1
μM of CaCl2 at 37°C for 1 hr to remove contaminating
plasmid DNA, and 100 ng of p24 was used to inoculate
100,000 HeLa-P4 cells per well. To test for potential
contaminating plasmid DNA in the virus stocks,
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Efavirenz, a reverse transcription inhibitor. After 8 hr,
cells were harvested and DNA isolated. To harvest the
cells, the supernatant was removed and the cells were
washed once with 1 ml of PBS and detached with tryp-
sin. Cells were pelleted and washed again with 0.5 ml of
PBS and the pellet resuspended in 100 μl PCR lysis buf-
fer (10 mM Tris–HCl, 1 mM EDTA, 0.2 mM CaCl2,
0.001% Triton X-100, 0.001% SDS, 1 mg/ml proteinase
K) and incubated at 58°C for 1 hr, followed by heat in-
activation at 95°C for 15 min. Viral DNA was quantified
by real-time PCR using an Stratagene MX-3000p instru-
ment with SYBR Green detection. The reaction mixture
contained 5 μl of infected lysate, 12.5 μl of 2X SYBR
Green PCR Master Mix (Roche), and 500 nM of each
primer. Second strand reverse transcription products
were amplified using 50-AGCAGCTGCTTTTTGCCTG
TACT-3 as the sense primer and 50-CCTGCGTCGA
GAGAGCTCCTCTGG-30, as the reverse primer. The
thermal cycling conditions were set at 50°C for 2 min
and 95°C for 10 min, followed by 40 cycles of 95°C for
15 s and 65°C for 45 s. We tested how much DNA was
loaded to qPCR reactions by measuring the absorbance
at 260 nm of the samples, and the quantities of DNA an-
alyzed were within 5% of one another.
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